Drugs / Bifidobacterium infantis M-63
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT02807064 Comparator | Dec 2016 → Jul 2018 | seasonal allergic rhinitis | University of Campania Luigi Vanvitelli | Unknown | No outcome recorded |
| Phase 4 | NCT02566876 Comparator | Dec 2013 → Jul 2015 | dyspepsia, irritable bowel syndrome | Federico II University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bifidobacterium infantis M-63 | “3 billions of Bifidobacterium longum BB536®, 1 billion of Bifidobacterium infantis M-63®, and 1 billion of Bifidobacterium breve M-16V®” NCT02566876 ↗ |
| Known as | B infantis M-63 | “Bifidobacterium mixture (B longum BB536, B infantis M-63, B breve M-16V) treatment in children with seasonal allergic rhinitis and intermittent asthma.” PMID 28270216 ↗ Mar 2017 |
| Modality | Other / unclassified | “probiotic mixture of Bifidobacterium infantis M-63, breve M-16V, and longum BB536” PMID 27306945 ↗ Jan 2017 |
| Route | Oral | “oral administration of a mixture of Bifidobacteria” NCT02566876 ↗ |